Type 2 diabetes medications, such as sulfonylureas, have been a mainstay of treating the disease since they came on the market in the early 1950s. However, although they are one of the most common ...
A comparative effectiveness research study compared MACE rates among initiators of sulfonylureas versus DPP4 inhibitors for T2D. Glipizide in particular showed a significant link to cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback